Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy

被引：30

作者：

Cadoo, Karen A. ^{[1
]}

Traina, Tiffany A. ^{[2
]}

King, Tari A. ^{[3
]}

机构：

[1] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10065 USA

[2] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med,Breast Canc Med Serv, New York, NY 10065 USA

[3] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Dept Surg,Breast Serv, New York, NY 10065 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2013年 / 22卷 / 04期

关键词：

Breast cancer; Intrinsic subtypes; Endocrine therapy; HER2; positive; Triple negative; Resistance; RANDOMIZED PHASE-II; GENE-EXPRESSION; ENDOCRINE THERAPY; TRASTUZUMAB RESISTANCE; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; TUMOR SUBTYPES; OPEN-LABEL; RECEPTOR; TAMOXIFEN;

D O I：

10.1016/j.soc.2013.06.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The identification of the intrinsic molecular subtypes of breast cancer has enhanced our understanding of tumor biology, informing therapeutic targets, and clinical trial design. This article reviews the intrinsic classification system and the clinically defined subtypes of breast cancer. We review the molecular drivers of each subtype and discuss implications for prognosis, clinical management, and future directions.

引用

页码：823 / +

页数：19

共 93 条

[1] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[2]

[Anonymous], J CLIN ONCOL S

[3] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[4] First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer [J].

Baselga, J. ;

Bradbury, I. ;

Eidtmann, H. ;

Di Cosimo, S. ;

Aura, C. ;

De Azambuja, E. ;

Gomez, H. ;

Dinh, P. ;

Fauria, K. ;

Van Dooren, V. ;

Paoletti, P. ;

Goldhirsch, A. ;

Chang, T-W ;

Lang, I. ;

Untch, M. ;

Gelber, R. D. ;

Piccart-Gebhart, M. .

CANCER RESEARCH, 2010, 70

[5]

Baselga J, 2012, CANC RES S24, V72

[6] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[7] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[8] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[9] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].

Baselga, Jose ;

Gelmon, Karen A. ;

Verma, Shailendra ;

Wardley, Andrew ;

Conte, PierFranco ;

Miles, David ;

Bianchi, Giulia ;

Cortes, Javier ;

McNally, Virginia A. ;

Ross, Graham A. ;

Fumoleau, Pierre ;

Gianni, Luca .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144

[10]

Beatson GT., 1896, LANCET, V148, P104

← 1 2 3 4 5 6 7 8 9 10 →